Authors
Latest:
Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic PopulationsWendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.
Latest:
Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 StudyWhitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.
Latest:
Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial CancersDoes renal disease increase one's risk of developing cancer?
Latest:
Oncologists Play Many Roles in Lung Cancer Screening ProgramsThe role of the oncologist is essential to the design, operation, development and associate research of lung cancer screening programs.
Latest:
Willem Overwijk Explains the Role of the Innate Immune System in Cancer TreatmentWillem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.
Latest:
Dr. Donnellan Discusses Trials in Hematologic MalignanciesWilliam B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.
Latest:
Dr. Huang on the Widespread Adoption of Robotic Surgery for Bladder SurgeryWilliam C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.
Latest:
Making Progress in Treating Relapse in Childhood LeukemiaHaving a robust armamentarium to treat childhood acute lymphoblastic leukemia (ALL) is a major triumph in oncology.
Latest:
Dr. Tap on Developing Treatment Opportunities in Soft Tissue SarcomasWilliam D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.
Latest:
Dr. Eward on the Unmet Need for Novel Agents for TGCT and SarcomaWilliam Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.
Latest:
Dr. Symmans on Moon Shots Program for Patients With TNBCWilliam F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.
Latest:
Dr. Symmans on the Staging System for Breast CancerWilliam F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.
Latest:
Dr. Blum on the Current Treatment Landscape of Acute Myeloid LeukemiaWilliam G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.
Latest:
Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLLWilliam G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Latest:
Dr Wierda on the Genomic Evolution of Pirtobrutinib in Pretreated CLLWilliam G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.
Latest:
Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 StudyWilliam G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.
Latest:
Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment AlgorithmWilliam Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.
Latest:
Future Directions in Care for HER2+ Breast CancerBefore closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Latest:
New Strategies Shift Landscape in HR+ Metastatic Breast CancerThere has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.
Latest:
Therapeutic Advances in Prophylaxis Against CINAn overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
Latest:
Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPCWilliam K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.
Latest:
Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate CancerWilliam K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.
Latest:
Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPCWilliam K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Dahut on the Future of Genetic Screening in Prostate CancerWilliam L. Dahut, MD, discusses the future of genetic screening in prostate cancer.
Latest:
Dr. Dahut on the Future of Genetic Screening in Prostate CancerWilliam L. Dahut, MD, discusses the future of genetic screening in prostate cancer.
